TMCnet News

Research and Markets: Atrial Fibrillation Therapeutics Pipeline Review 2015 - 15 Companies & 25 Drug Profiles
[February 26, 2015]

Research and Markets: Atrial Fibrillation Therapeutics Pipeline Review 2015 - 15 Companies & 25 Drug Profiles


Research and Markets (http://www.researchandmarkets.com/research/fcjwkf/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens Ramp;D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.



Companies Involved in Therapeutics Development

  • ARCA biopharma, Inc.
  • Armetheon, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Cardiome Pharma Corp
  • Daiichi Sankyo Company, Limited
  • Gilead Sciences, Inc.
  • Isis Pharmaceuticals, Inc.
  • Laboratoires Pierre Fabre SA
  • Nissan Chemical Industries, Ltd.
  • Nyken BV
  • Otsuka Holdings Co., Ltd.
  • Regado Biosciences, Inc.
  • Serodus ASA
  • Xention Limited

Drug Profiles


  • (ranolazine + dronedarone)
  • Aptamers for Cardiovascular Diseases
  • BMS-919373
  • bucindolol hydrochloride
  • budiodarone
  • Drug For Atrial Fibrillation
  • edoxaban tosylate
  • F-373280
  • GsMTx-4
  • ISIS-CRPRx
  • NIP-151
  • NYK-1112
  • OMT-33
  • OPC-108459
  • ranolazine ER
  • SER-102
  • Small Molecule to Block IKACh for Atrial Fibrillation
  • Small Molecule to Block Kv1.5 for Atrial Fibrillation
  • Small Molecules to Activate Heat Shock Protein 70 (Hsp70) for Post-Operative Atrial Fibrillation
  • Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation
  • vanoxerine
  • vernakalant hydrochloride
  • XEN-D0101
  • XEN-D0103
  • XEN-R0702

For more information visit http://www.researchandmarkets.com/research/fcjwkf/atrial


[ Back To TMCnet.com's Homepage ]